News about Cosmos Health

CEO Greg Siokas said preliminary nine-month revenue reached about $54.3 million, up 19% year over year, and the company reaffirmed that full-year 2026 revenue will surpass $90 million. The letter notes 2025 revenue of a record $65.3 million, with gross profit up 83% to $7.9 million and gross margin at 12.1%. Reaching the outlook implies fourth-quarter 2026 revenue of about $35.7 million or more, roughly 81% above the approximately $19.7 million of the fourth quarter of 2025. Its newly launched U.S. direct-to-consumer e-commerce business had 8,940 subscriptions and is expected to generate about $15 million in fourth-quarter revenue. The company's proprietary brands are sold in more than 40 countries.

Cosmos Health CEO Greg Siokas wrote to shareholders that preliminary nine-month 2026 revenue was about $54.3 million, up 19%, and the company reaffirmed full-year revenue above $90 million, up about 38%. Fourth-quarter revenue is expected to be about $35.7 million or more, up roughly 81% from the same quarter of 2025, driven by pharmaceutical contract manufacturing and distribution, proprietary brands and U.S. e-commerce. U.S. e-commerce had 8,940 active subscriptions as of October 19, 2026, up 42% in five days, and is expected to generate about $15 million in fourth-quarter revenue. The company also repurchased more than 5.1 million shares for about $1.1 million and set 2029 targets of $200.6 million in revenue and $44.2 million in adjusted EBITDA, with the goal of becoming self-funding by 2027.